OxiGene 'Leader' In Approach Of Vascular Targeting For Cancer
By Randall Osborne
Monday, July 14, 2003
Gone are the days when a dollop of good news in any area of biotechnology lit a fire under stocks across the sector. Investors, having become at least somewhat more sophisticated, have narrowed their scrutiny to individual companies or platforms.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.